International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the  Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing more...


  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 43

PDF Downloaded: 13


Mahmood: Gene mutation can be treated in breast cancer by gene therapy


Introduction

Cancer also known as malignant neoplasm, is a broad group of various diseases. In cancer, cells divide and grow uncontrollably, forming malignant tumours, and invade nearby parts of the body. There are over 200 different known cancers that afflict humans. Malignant neoplastic lesions are the sixth leading cause accounting for 4.7% of the total medically certified deaths in India.1

Breast cancer is by far the most frequent cancer among women with an estimated 1.38 million new cancer cases diagnosed in 2008 (23% of all cancers), and ranks second overall (10.9% of all cancers). It is now the most common cancer both in developed and developing regions with around 690000 new cases estimated in each region (population ratio1:4).2 Breast cancer is the Most Common cancer in all urban areas the world, and 2nd most common in the rural areas.3, 4 The most recent data Population Based Cancer Registry PBCR 2016 - 2018 tells us that breast cancer accounts for 35% to 40% of all cancers in women. Breast cancer alone accounts for around 18% of total female neoplasm deaths.5 Breast cancer is a malignant proliferation of epithelial cells lining the ducts or lobules of the breast.6 Human breast cancer is a clonal disease. A single transformed cell is the product of a series of somatic (acquired) or germ line mutations is eventually able to express full malignant potential.7 Thus, breast cancer may exist for a long period as either a non invasive disease or an invasive but non metastatic disease. These facts have significant clinical ramifications.8 There are specific genetic mutations that can predispose individuals to developing breast cancer and other cancers, and mutations in these genes can account for approximately 5% of all breast cancers. These genes include BRCA1, BRCA2, p53 and PTEN. The BRCA1 gene is located on chromosome 17. This gene is mutated in families with early-onset breast and ovarian cancer. Breast cancer will develop in approximately 85% of women with BRCA1 gene mutations during their lifetime.9, 10

Materials and Methods

A total number of 100 patients and 50 healthy controls were taken for the study. This study was conducted at The Departments of Gynaecology & Obstetrics, Biochemistry, Physiology and Pahtology Owaisi Hospital & Research Centre. (a teaching hospital to Deccan College of Medical Sciences, Hyderabad, T.S. India) The cases and samples were collected from female breast cancer patients presenting and admitted to the department of Surgical oncology, Medical oncology, Radiation Oncology. Owaisi Hospital & Research Centre. (a teaching hospital to Deccan College of Medical Sciences, Hyderabad, T.S. India) This prospective study was carried out on 100 patients and 50 healthy controls. The invasive duct carcinoma otherwise specified benign breast lesions including fibroadema and fibrocystic disease. Fresh tissues were taken, which were then subjected to RNA extraction.11 The BCL mRNA level was assessed using real- time reverse transcription Polymerase Chain Reaction (PCR).12

Results

There was significant higher levels of BCL6 mRNA in malignant cases compared to healthy controls (p<0.001). The level of BCL6 mRNA was higher in cases showing advanced tumor stage (p<0.04), triple negative subtype and associated in situ component (p<0.001) compared to cases with an early stage, luminal or Her 2-neu positive subtypes and those lacking in situ component.6, 13 These genes include BRCA1, BRCA2, p53 and PTEN.14

Discussion

Risks of breast cancer was determined with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2. We selected 100 index cases, regardless of family history of cancer, and carried out molecular analysis across entire families. The lifetime risk of breast cancer among female mutation carriers was 82%, similar to risks in families with many cases. Risks appear to be increasing with time: Breast cancer risk by age 50 among mutation carriers born before 1940 was 24%, but among those born after 1940 it was 67%. Lifetime risks of breast cancer was 54% for BRCA1 and 23% for BRCA2 mutation carriers.

Conclusion

BCL6 is up-regulated in breast cancer and is associated with poor prognostic features such as advanced stage an triple negative molecular subtype. BCL6 inhibitors might be considered as targeted therapy for breast cancer. These genes include BRCA1, BRCA2, p53 and PTEN.

Source of Funding

None.

Conflict of Interest

The authors declare no conflict of interest.

References

1 

SA Narod WD Foulkes BRCA1 and BRCA2: 1994 and beyondNat Rev Cancer20044966576

2 

D Ford DF Easton M Stratton S Narod D Goldgar P Devilee Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage ConsortiumAm J Hum Genet19986236768910.1086/301749

3 

P Smith L McGuffog DF Easton GJ Mann GM Pupo B Newman A genome wide linkage search for breast cancer susceptibility genesGenes Chromosomes Cancer20064576465510.1002/gcc.20330

4 

PDP Pharoah AC Antoniou DF Easton BAJ Ponder Polygenes, risk prediction, and targeted prevention of breast cancerN Engl J Med200835826279680310.1056/NEJMsa0708739

5 

TA Manolio FS Collins NJ Cox DB Goldstein LA Hindorff DJ Hunter Finding the missing heritability of complex diseasesNature200946172657475310.1038/nature08494

6 

MSY Huen R Grant I Manke K Minn X Yu MB Yaffe RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assemblyCell200713159011410.1016/j.cell.2007.09.041

7 

ME Moynahan M Jasin Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesisNat Rev Mol Cell Biol2010113196207

8 

PJ O’donovan DM Livingston BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repairCarcinogenesis20103169617

9 

G Chinnadurai The transcriptional corepressor CtBP: a foe of multiple tumor suppressorsCancer Res20096937314

10 

Q Zhang DW Piston RH Goodman Regulation of corepressor function by nuclear NADHScience2002295556118957

11 

CC Fjeld WT Birdsong RH Goodman Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensorProc Natl Acad Sci USA20031001692029

12 

NK Kolas JR Chapman S Nakada J Ylanko R Chahwan FD Sweeney Orchestration of the DNA-damage response by the RNF8 ubiquitin ligaseScience20073185856163740

13 

C Doil N Mailand SB Jensen P Menard DH Larsen R Pepperkok RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteinsCell2009136343546

14 

J R Morris The SUMO modification pathway is involved in the BRCA1 response to genotoxic stressNature2009462727588690



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article type

Original Article


Article page

237-238


Authors Details

Shaikh Mahmood*


Article History

Received : 25-08-2021

Accepted : 03-09-2021

Available online : 08-10-2021


Article Metrics


View Article As

 


Downlaod Files

   








Wiki in hindi